About us
Our goal is to translate scientific advances in RNA Nanotechnology to improve the therapeutic outcomes and lives of our patients
ExonanoRNA is a platform biotechnology company developing a new class of RNA nanotechnology-based therapeutics for cancer treatment. Our proprietary RNA NanoParticles (RNP) are designed to unlock the potential of RNA therapeutics in a range of cancer disease treatment. RNA Nanotechnology enables cancer cell-specific delivery of siRNA, miRNA, and chemo drugs with significantly enhanced efficacy and reduced toxicity. Our pharmaceutical R&D focuses on addressing treatment for late-stage oncology diseases.
What We Do
Pharmaceutical R&D
Products and Services for RNA Nanotechnology
Pharmaceutical R&D
RNA NanoParticle Delivery System (RNP)
Our RNA NanoParticle Delivery System (RNP) creates a unique nano-scaffold conjugated with small therapeutic RNA molecules and chemotherapeutic drugs that result in extraordinary pharmacokinetic and pharmacodynamic properties.
RNA NANOPARTICLE (RNP) PLATFORM:
- The negative charge of RNP prevents nonspecific binding to cells
- The defined structure and size (10-40nm) avoids immune system clearance
- Targets tumors through enhanced permeability and retention (EPR) effect and by active targeting of ligands on RNP
- Favorable PK profiles in mice:
- T1/2: 5-10hr compared to 0.25-0.76hr of siRNA
- Biodistribution: mainly in the tumor but no other healthy organs.
- High delivery efficiency: ~5% compared to 0.7% using other nanoparticles
- Low toxicity: no toxicity after repeated IV up to 30mg/kg in mice
- Low immunogenicity: does not induce interferon or cytokine responses
RNA Nanoparticles Displaying Exosomes Delivery System (ExRNA)
ExRNA exosomes deliver nucleic acid-based therapeutics to treat life-threatening diseases. We harnessed the natural delivery capabilities of exosomes and specific targeting properties of RNA nanoparticles to create a novel class of biotherapeutics.
ExRNA PLATFORM:
- Displaying RNA nanoparticles on the exosome’s surface makes the ExRNA negatively charged, which prevents nonspecific binding to cells.
- Displaying RNA nanoparticles with an aptamer or chemical ligand enhances its targeting efficiency.
- ExRNA effectively delivers siRNA to the cell cytoplasm, escaping endosome trapping
- Validated in mouse model systems
OUR TEAM
Peixuan Guo, PhD
Founder, Board Director, Chairman of Scientific Advisory Committee
Michael Li MD, PhD
VP, Board Director
Gary Li MD
Board Director